Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TAP binding protein-like (TAPBPL) is a cell-surface glycoprotein and member of the immunoglobulin superfamily that is structurally related to the B7 family. Expressed on T cells, antigen-presenting cells (B cells, monocytes, macrophages, dendritic cells), and some tumor tissues, TAPBPL functions as a negative regulator of T cell responses. It binds to MHC class I complexes and modulates antigen processing and presentation. TAPBPL suppresses T cell activation and proliferation; a soluble TAPBPL-Fc fusion protein has been shown to reduce autoimmune disease severity in mice, while blocking its activity with antibodies enhances antitumor immune responses. Thus, TAPBPL represents a novel immune checkpoint with potential implications in cancer immunotherapy, autoimmune disease, and infection
TAPBPL-Ig: inhibits T cell proliferation, activation, and cytokine production anti-TAPBPL antibody: blocks TAPBPL inhibitory activity, enhancing antitumor immunity
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TAP binding protein-like (TAPBPL).